Urolithin A.

Urolithin A acts on mitophagy, the recycling of worn mitochondria, while nicotinamide riboside raises the NAD+ pool that sirtuin signalling and mitochondrial biogenesis draw on. One side clears, the other side rebuilds, so they act on different steps of the same turnover cycle.

Spermidine induces general autophagy largely by inhibiting the acetyltransferase EP300, while urolithin A acts more selectively on mitophagy. The routes into the recycling machinery are distinct rather than redundant.

Urolithin A promotes mitophagy, the clearance of damaged mitochondria, while NAD precursors supply the cofactor that the remaining mitochondria run on. Clearance and fuelling are separate limits.

Renewing the mitochondrial pool only helps if the electron carriers inside are present. Coenzyme Q10 fills the carrier role that urolithin A does not touch.

Pterostilbene acts on sirtuin and PGC-1 alpha signalling that drives new mitochondrial synthesis, the counterpart to the clearance urolithin A promotes. Turnover needs both halves.

Resveratrol engages the AMPK and sirtuin route toward making new mitochondria while urolithin A clears damaged ones. The pairing covers both directions of turnover.

Leucine triggers mTOR-driven muscle protein synthesis, an anabolic signal distinct from the mitochondrial housekeeping urolithin A supports. In older adults the two limits are different.

HMB acts mainly on reducing protein breakdown in muscle, while urolithin A works on mitochondrial quality within the same tissue. Their targets do not overlap.

Creatine buffers phosphate transfer for short bursts of work, sitting downstream of the mitochondria urolithin A renews. Both contribute to how much work muscle can sustain in older adults.

Fisetin acts on clearance of senescent cells while urolithin A acts on clearance of damaged mitochondria within surviving cells. The two work at different scales of the same housekeeping problem.

Urolithin A is not present in food. Dietary ellagitannins are hydrolysed to ellagic acid in the upper gut, and specific colonic bacteria then convert ellagic acid through a series of dehydroxylation steps to urolithin A. Supplying ellagic acid raises the substrate available for that conversion, though the amount of urolithin A produced depends on which bacteria a person carries.

Punicalagins from pomegranate release ellagic acid in the gut, which the resident microbiota may then convert onward to urolithin A. This is the classical dietary route to the metabolite. Conversion is partial and person-dependent, so a pomegranate dose does not translate into a predictable urolithin A exposure.

Only a subset of people carry the bacterial consortia that finish the conversion of ellagic acid to urolithin A, which is why the same pomegranate dose gives very different metabolite levels between individuals. A multi-species synbiotic was reported to raise urolithin A alongside butyrate production. The finding is about a metabolite level, which is a marker rather than a clinical outcome.

Butyrate and urolithin A are both end products of colonic fermentation, and the same synbiotic intervention raised both together. They act on different targets, butyrate on colonocyte energy supply and urolithin A on mitochondrial turnover. The overlap here is production route, not a demonstrated combined effect.

Inulin feeds saccharolytic colonic bacteria and shifts the fermentation environment in which ellagic acid conversion happens. The mechanistic case is a supported microbiota rather than a direct chemical interaction with urolithin A. Whether it raises urolithin A output in a given person has not been established.

Galactooligosaccharides selectively feed bifidobacteria and shift colonic pH downward. That environment is where ellagic acid conversion takes place. Read this as mechanistic plausibility, not as a measured increase in urolithin A.

Resistant starch reaches the colon intact and supports the fermentative bacteria that also handle polyphenol metabolism. It is a substrate-level input to the same community. No study has tied resistant starch intake to a specific change in urolithin A output.

Urolithin A is a poorly water-soluble dibenzopyranone, so its dissolution in the gut lumen limits how much reaches the enterocyte. Medium-chain triglycerides provide a lipid phase that keeps it dispersed. This is a formulation rationale about exposure, not a claim about a bigger biological effect.

Lecithin phospholipids form mixed micelles that carry lipophilic polyphenols across the unstirred water layer. Urolithin A is a common candidate for this kind of dispersion because of its low solubility. The pairing is formulation practice rather than a pharmacological synergy.

Phosphatidylcholine complexes are a standard way to disperse lipophilic plant metabolites in the intestinal lumen. Applied to urolithin A, the aim is dissolution rather than any change in its target biology. The rationale is physicochemical.

Alpha-lipoic acid is the cofactor for pyruvate and alpha-ketoglutarate dehydrogenase, sitting inside the same organelle whose turnover urolithin A influences. One supports substrate flux into the Krebs cycle, the other supports removal of damaged mitochondria. The pairing is mechanistically coherent and has not been measured as a combination in people.

Carnitine palmitoyltransferase requires carnitine to move long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Urolithin A acts on the quality control side, promoting turnover of damaged mitochondria. Substrate delivery and organelle quality are different levers on the same compartment.

Riboflavin is the precursor of FMN and FAD, which sit inside complexes I and II of the electron transport chain. Mitochondrial capacity that urolithin A helps maintain still depends on those flavin cofactors being present. This is a cofactor dependency rather than a tested combination.

Essentially every ATP-utilising enzyme binds ATP as Mg-ATP, so magnesium status sits underneath any mitochondrial output. Urolithin A influences mitochondrial turnover, not magnesium handling. The relationship is a dependency of the downstream chemistry.

Astaxanthin partitions into phospholipid membranes, including mitochondrial membranes, where it intercepts lipid radicals. Urolithin A acts on the recycling of damaged organelles rather than on lipid peroxidation directly. The two sit on different arms of the same redox problem and have not been studied together.

Whey supplies leucine-rich amino acids that stimulate muscle protein synthesis after loading. Urolithin A has been examined for mitochondrial quality in muscle rather than for protein accretion. Combining an amino acid stimulus with a mitochondrial one is mechanistically sensible and has not been formally tested as a pair.

Taurine conjugates onto mitochondrial tRNA wobble bases, and without that modification several electron transport subunits are translated poorly. Urolithin A acts further downstream on organelle turnover. Both converge on mitochondrial competence from different directions.

Urolithin A undergoes heavy phase II glucuronidation in the intestinal wall and liver, which is why circulating parent compound stays low. Piperine slows glucuronidation of several polyphenols. The interaction class is established for piperine generally; the specific effect on urolithin A glucuronides has not been quantified.

EPA and DHA are esterified into membrane phospholipids including cardiolipin-adjacent pools, which shapes inner membrane fluidity. Urolithin A acts on the turnover of those membranes rather than their composition. The combination is mechanistically adjacent and untested as a pair.